去勢抗性攝護腺癌治療進展

Advance in the Treatment of Castration-resistant Prostate Cancer

江吉文(Chi-Wen Chiang)

攝護腺癌 ； 雄性素去除療法 ； 去勢抗性攝護腺癌 ； 臨床試驗 ； Prostate cancer ； Androgen deprivation therapy ； Castration-resistant prostate cancer ； Clinical trial

醫學與健康期刊

11卷3期（2022 / 11 / 01）

1 - 13

繁體中文

臺灣男性攝護腺癌發病率逐漸增加，2020年攝護腺癌位居我國男性癌症死因第6位。雄性素去除療法一直是晚期或轉移性攝護腺癌初始治療的標準。初始雄性素去除療法雖效果明顯，但治療1－2年後，攝護腺癌可能會對雄性素去除療法產生耐受，進展為去勢抗性攝護腺癌，治療上相對棘手。過去十年已有多種藥物核准上市用於治療去勢抗性攝護腺癌，包括：化學治療、內分泌治療、免疫治療、靶向治療、骨轉移治療。本文重點介紹與去勢抗性攝護腺癌治療相關的藥物臨床試驗。

In Taiwan, the incidence of prostate cancer in men is gradually increasing. Prostate cancer is the sixth leading cause of cancer deaths in Taiwanese men in 2020. Androgen deprivation therapy (ADT) has been the standard of care for initial treatment of advanced or metastatic prostate cancer. Although initial ADT is effective, after one to two years of treatment, the cancer may become resistant to ADT and progress to castration-resistant prostate cancer (CRPC), which is relatively difficult to treat. A number of drugs have been approved for the treatment of CRPC in the last decade, including: chemotherapy, endocrine therapy, immunotherapy, targeted therapy and bone metastasis therapy. This article focuses on clinical trials of drugs related to the treatment of CRPC.

1. Abida, W,Patnaik, A,Campbell, D(2020).Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration.J Clin Oncol,38,3763-3772.
2. Antonarakis, ES,Piulats, JM,Gross-Goupil, M(2020).Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study.J Clin Oncol,38,395-405.
3. Beer, TM,Armstrong, AJ,Rathkopf, D(2017).Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: Extended analysis of the phase 3 PREVAIL study.Eur Urol,71,151-154.
4. Beer, TM,Kwon, ED,Drake, CG(2017).Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer.J Clin Oncol,35,40-47.
5. Cornford, P,van den Bergh, RCN,Briers, E(2021).EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer.Eur Urol,79,263-282.
6. de Bono, JS,Oudard, S,Ozguroglu, M(2010).Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.Lancet,376,1147-1154.
7. Eisenberger, M,Hardy-Bessard, AC,Kim, CS(2017).Phase III study comparing a reduced dose of cabazitaxel (20mg/m2) and the currently approved dose (25mg/m2) in postdoce-taxel patients with metastatic castration-resistant prostate cancer-PROSELICA.J Clin Oncol,35,3198-3206.
8. Fizazi, K,Carducci, M,Smith, M(2011).Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.Lancet,377,813-822.
9. Fizazi, K,Scher, HI,Molina, A(2012).Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.Lancet Oncol,13,983-992.
10. Fizazi, K,Shore, N,Tammela, TL(2020).Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide.N Engl J Med,383,1040-1049.
11. Fizazi, K,Shore, N,Tammela, TL(2019).Darolutamide in nonmetastatic, castration-resistant prostate cancer.N Engl J Med,380,1235-1246.
12. Graff, JN,Beer, TM,Alumkal, JJ(2020).A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.J Immunother Cancer,8,e000642.
13. Huggins, C,Hodges, CV(1972).Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.CA Cancer J Clin,22,232-240.
14. Hussain, M,Fizazi, K,Saad, F(2018).Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer.N Engl J Med,378,2465-2474.
15. Hussain, M,Mateo, J,Fizazi, K(2020).Survival with olaparib in metastatic castration-resistant prostate cancer.N Engl J Med,383,2345-2357.
16. Kantoff, PW,Higano, CS,Shore, ND(2010).Sipuleucel-T immunotherapy for castration-resistant prostate cancer.N Engl J Med,363,411-422.
17. Lin, PH,Chang, SW,Tsai, LH(2020).Increasing incidence of prostate cancer in Taiwan: a study of related factors using a nationwide health and welfare database.Medicine,99,e22336.
18. Mateo, J,Carreira, S,Sandhu, S(2015).DNA-repair defects and olaparib in metastatic prostate cancer.N Engl J Med,373,1697-1708.
19. Mateo, J,Porta, N,Bianchini, D(2020).Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.Lancet Oncol,21,162-174.
20. Ministry of Health and Welfare in Taiwan. 2020 statistics of causes of death. Available at: https://dep.mohw.gov.tw/DOS/cp-5069-62791-113.html. Accessed February 21, 2022.
21. Nuhn, P,De Bono, JS,Fizazi, K(2019).Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology.Eur Urol,75,88-99.
22. Oudard, S,Fizazi, K,Sengeløv, L(2017).Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA.J Clin Oncol,35,3189-3197.
23. Parker, C,Nilsson, S,Heinrich, D(2013).Alpha emitter radium-223 and survival in metastatic prostate cancer.N Engl J Med,369,213-223.
24. Petrylak, DP,Tangen, CM,Hussain, MH(2004).Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.N Engl J Med,351,1513-1520.
25. Ryan, CJ,Smith, MR,Fizazi, K(2015).Abiraterone acetate plus prednisone versus placebo plus prednisone in chemo-therapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.Lancet Oncol,16,152-160.
26. Sartor, O,de Bono, J,Chi, KN(2021).Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer.N Engl J Med,385,1091-1103.
27. Scher, HI,Fizazi, K,Saad, F(2012).Increased survival with enzalutamide in prostate cancer after chemotherapy.N Engl J Med,367,1187-1197.
28. Smith, MR,Saad, F,Chowdhury, S(2021).Apalutamide and overall survival in prostate cancer.Eur Urol,79,150-158.
29. Smith, MR,Saad, F,Chowdhury, S(2018).Apalutamide treatment and metastasis-free survival in prostate cancer.N Engl J Med,378,1408-1418.
30. Sternberg, CN,Fizazi, K,Saad, F(2020).Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer.N Engl J Med,382,2197-2206.
31. Tannock, IF,de Wit, R,Berry, WR(2004).Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med,351,1502-1512.
32. Tannock, IF,Osoba, D,Stockler, MR(1996).Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.J Clin Oncol,14,1756-1764.